About: Saredutant

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Saredutant Goto Sponge NotDistinct Permalink

An Entity of Type : yago:WikicatAcetanilides, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/c/4xBzYnu9cq

Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.

Attributes	Values
rdf:type	Thing dul:ChemicalObject chemical substance Drug yago:WikicatAntidepressants yago:WikicatAnxiolytics yago:Acetanilide102674912 yago:Agent114778436 yago:Analgesic102707683 yago:Antidepressant102718811 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Matter100020827 yago:Medicine103740161 yago:MinorTranquilizer103771443 yago:PhysicalEntity100001930 yago:PsychotropicAgent104017429 drug yago:Sedative-hypnotic104166841 yago:Sedative104166553 yago:Substance100020090 yago:Tranquilizer104470232 yago:WikicatAcetanilides
rdfs:label	Sarédutant (fr) Saredutant (en)
rdfs:comment	Sarédutant ou SR 48968, est un antagoniste des récepteurs neurokinie-2 développé par Sanofi Aventis pour lutter contre la dépression (antidépresseur) et l'anxiété (anxiolytique). En 2007 il est en phase 3 du développement clinique. En mai 2009, Sanofi-Aventis publie ses résultats trimestriels, et annonce l'arrêt de 14 projets de recherche-développement, dont le sarédutant en phase 3, dans le traitement de la dépression. (fr) Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder. (en)
foaf:depiction
dcterms:subject	4-Phenylpiperidines Chloroarenes Experimental drugs NK2 receptor antagonists Antidepressants Anxiolytics Benzamides Acetanilides
Wikipage page ID	7803166 (xsd:integer)
Wikipage revision ID	1075461735 (xsd:integer)
Link from a Wikipage to another Wikipage	GR-159,897 4-Phenylpiperidines Chloroarenes Experimental drugs Tachykinin receptor 2 Phase III clinical trials Antidepressant Anxiolytic Major depressive disorder Clinical trial NK2 receptor antagonists Receptor antagonist Drug Antidepressants Anxiolytics Benzamides Acetanilides Ibodutant Nepadutant Sanofi-Aventis
sameAs	Saredutant Saredutant Saredutant Saredutant Saredutant Saredutant Saredutant
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Antidepressants dbt:Anxiolytics dbt:Neurokinin_receptor_modulators
thumbnail	wiki-commons:Special:FilePath/Saredutant.svg?width=300
ATC prefix	none (en)
c	31 (xsd:integer)
CAS number	142001 (xsd:integer)
ChEMBL	308148 (xsd:integer)
ChemSpiderID	94726 (xsd:integer)
Cl	2 (xsd:integer)
H	35 (xsd:integer)
IUPAC name	N-[-4-- 2-butyl]-N-methylbenzamide (en)
n	3 (xsd:integer)
O	2 (xsd:integer)
PubChem	104974 (xsd:integer)
SMILES	Clc1ccc[C@H]CNC (en)
StdInChI	1 (xsd:integer)
StdInChIKey	PGKXDIMONUAMFR-AREMUKBSSA-N (en)
UNII	720 (xsd:integer)
Verifiedfields	changed (en)
verifiedrevid	464387259 (xsd:integer)
Watchedfields	changed (en)
width	250 (xsd:integer)
has abstract	Sarédutant ou SR 48968, est un antagoniste des récepteurs neurokinie-2 développé par Sanofi Aventis pour lutter contre la dépression (antidépresseur) et l'anxiété (anxiolytique). En 2007 il est en phase 3 du développement clinique. En mai 2009, Sanofi-Aventis publie ses résultats trimestriels, et annonce l'arrêt de 14 projets de recherche-développement, dont le sarédutant en phase 3, dans le traitement de la dépression. (fr) Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist. It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder. (en)

Faceted Search & Find service v1.17_git147 as of Sep 06 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3332 as of Dec 5 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 71 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software